Olivamine-induced improvement in endothelial cells viability and function

2:

• The composition of claim 1, wherein the administration of the composition reduces the time required for healing of the wound by at least about 30% in comparison to a wound treated with the endothelial cells alone.

(canceled)

4:

• The composition of claim 1, wherein the primary vascular endothelial cells are derived from umbilical cord blood and are umbilical cord stem cells, or wherein said endothelial cells are provided in the form of a medium conditioned by endothelial cells or growth factors which are beneficially increased as a result of an endothelial stem cell transplant.

5:

• The composition of claim 1 wherein said primary vascular endothelial cells are human endothelial cells.

6:

• The composition of claim 5 wherein said human endothelial cells are microvascular endothelial cells.

7:

• The composition according to claim 1, wherein the ratio of hydroxytyrosol to oleuropein is front about 1:1 to about 10:1.

8:

• The composition according to claim 1, wherein the composition further comprises N-acetyl cysteine, glycine, taurine and L-proline.

9:

• The composition according to claim 8, wherein the weight ratio of N-acetyl cysteine to hydroxytyrosol is between 1:1 and 50:1, wherein the weight ratio of glycine to hydroxytyrosol is between 1:1 and 50:1, wherein the ratio of taurine to hydroxytyrosol is between 1:1 and 50:1, and wherein the weight ratio of L-proline to hydroxytyrosol is between 1:1 and 20:1.

10:

• The composition according to claim 9, wherein the composition has a concentration of hydroxytyrosol less than 225 μM and a concentration of oleuropein less than 900 μM.

11:

• The composition according to claim 9, wherein the composition has a concentration of hydroxytyrosol less than 15 μM and a concentration of oleuropein less than 60 μM.

13:

• The method according to claim 12, wherein the wound healing further comprises promoting keratinocyte and fibroblast proliferation and/or neovascularization.

14:

• The method according to claim 12, wherein the endothelial cells are derived from umbilical cord blood and are umbilical cord stem cells, or a cultured medium conditioned by said umbilical cord stem cells.

15:

• The method according to claim 12, wherein the ratio of hydroxytyrosol to oleuropein is from about 1:1 to about 10:1.

16:

• The method according to claim 12, wherein the composition further comprises N-acetyl cysteine, glycine, taurine and L-proline.

17:

• The method according to claim 16, wherein the weight ratio of N-acetyl cysteine to hydroxytyrosol is between 1:1 and 50:1, wherein the weight ratio of glycine to hydroxytyrosol is between 1:1 and 50:1, wherein the ratio of taurine to hydroxytyrosol is between 1:1 and 50:1, and wherein the weight ratio of L-proline to hydroxytyrosol is between 1:1 and 20:1.

18:

• The method according to claim 12, wherein weight ratio N-acetyl cysteine to hydroxytyrosol is between 10:1 and 30:1, the weight ratio glycine to hydroxytyrosol is between 30:1 and 40:1, the weight ratio of taurine to hydroxytyrosol is between 20:1 and 50:1, and wherein the weight ratio of L-proline to hydroxytyrosol is between 1:1 and 10:1.

19:

• The method according to claim 12, wherein the time required for healing at least 50% of a wound is reduced to below at least 8 hours.